Merck (MRK) also had above average risk, with their at-risk products making up 56% of 2024 revenue...financial situation in 2025 is exacerbated exponentially.

.The disease areas with the most significant number of FDA approvals in 1St half
of 2024;
Oncology with:29 approvals (34.94%)

Autoimmune/Inflammation:11 approvals (13.25%)

Looking for 2025 Stats..so far looks like mixed bag.